Skip to main content
. 2022 Oct 10;21(2):170–186. doi: 10.1158/1541-7786.MCR-22-0486

Figure 1.

Figure 1. TWEAK activates classic and alternative NF-κB pathways in ovarian cancer cell lines and patient-derived cells. A, Luciferase reporter assay showing NF-κB activity in response to 24-hour stimulation with different cytokines (n = 3). B, DNA-binding of NF-κB proteins with TWEAK stimulation (25 ng/mL) for 2 or 24 hours relative to vehicle. One-way ANOVA with Dunnett post hoc (n = 3). C, Nuclear and cytosolic western blots of NF-κB proteins with TWEAK (25 ng/mL, 0, 2, or 24 hours) in CAOV4, OVCAR8, and OV90. D, Nuclear and cytosolic western blots of NF-κB proteins with TWEAK (100 ng/mL, 24 hours) stimulation in ascites sample VBCF004. Data represent mean and SEM. *, P < 0.05.

TWEAK activates classic and alternative NF-κB pathways in ovarian cancer cell lines and patient-derived cells. A, Luciferase reporter assay showing NF-κB activity in response to 24-hour stimulation with different cytokines (n = 3). B, DNA-binding of NF-κB proteins with TWEAK stimulation (25 ng/mL) for 2 or 24 hours relative to vehicle. One-way ANOVA with Dunnett post hoc test (n = 3). C, Nuclear and cytosolic western blots of NF-κB proteins with TWEAK (25 ng/mL, 0, 2, or 24 hours) in CAOV4, OVCAR8, and OV90. D, Nuclear and cytosolic western blots of NF-κB proteins with TWEAK (100 ng/mL, 24 hours) stimulation in ascites sample VBCF004. Data represent mean and SEM. *, P < 0.05.